{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:34:58Z","timestamp":1791506098495,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.phrs.2021.105573","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T03:48:38Z","timestamp":1616471318000},"page":"105573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials"],"prefix":"10.1016","volume":"169","author":[{"given":"Jieli","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongsheng","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haochen","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-0209","authenticated-orcid":false,"given":"Dongye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongda","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10120","key":"10.1016\/j.phrs.2021.105573_bib1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2021.105573_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2021.105573_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"8","key":"10.1016\/j.phrs.2021.105573_bib4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"23","author":"Yancy","year":"2017","journal-title":"J. Cardiac Fail."},{"issue":"24","key":"10.1016\/j.phrs.2021.105573_bib5","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat. Med."},{"issue":"9","key":"10.1016\/j.phrs.2021.105573_bib6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Euro. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail."},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2021.105573_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.118.006951","article-title":"Efficacy of pharmacologic and cardiac implantable electronic device therapies in patients with heart failure and reduced ejection fraction","volume":"12","author":"Tseng","year":"2019","journal-title":"Circ. Arrhythmia Electrophysiol."},{"issue":"9","key":"10.1016\/j.phrs.2021.105573_bib10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"20","key":"10.1016\/j.phrs.2021.105573_bib11","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med."},{"issue":"7\u20138","key":"10.1016\/j.phrs.2021.105573_bib12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Making"},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2021.105573_bib15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.phrs.2021.105573_bib16","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation: the prime study","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.phrs.2021.105573_bib17","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","article-title":"Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure","volume":"106","author":"Vizzardi","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105573_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","article-title":"Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","volume":"3","author":"Udelson","year":"2010","journal-title":"Circ. Heart Fail."},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Euro. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2007.02.016","article-title":"Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure","volume":"125","author":"Kum","year":"2008","journal-title":"Int. J. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105573_bib21","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2967\/jnumed.107.045427","article-title":"Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure","volume":"48","author":"Kasama","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.phrs.2021.105573_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/hrt.2005.062463","article-title":"Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure","volume":"92","author":"Kasama","year":"2006","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib23","first-page":"344","article-title":"A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy","volume":"21","author":"Tatli","year":"2005","journal-title":"Can. J. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105573_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.fjc.0000159880.12067.34","article-title":"Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure","volume":"45","author":"Palazzuoli","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejheart.2004.10.015","article-title":"Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study","volume":"7","author":"Edes","year":"2005","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/B:CARD.0000025756.32499.6f","article-title":"The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)","volume":"18","author":"Remme","year":"2004","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2021.105573_bib27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejheart.2003.12.007","article-title":"Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure","volume":"6","author":"Cohen","year":"2004","journal-title":"Euro. J. Heart Fail."},{"issue":"9377","key":"10.1016\/j.phrs.2021.105573_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(03)13801-9","article-title":"Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial","volume":"362","author":"Cleland","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2021.105573_bib29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1388-9842(02)00114-9","article-title":"Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure","volume":"4","author":"Palazzuoli","year":"2002","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib30","doi-asserted-by":"crossref","first-page":"A14","DOI":"10.1067\/mhj.2002.121807","article-title":"Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure","volume":"144","author":"de Milliano","year":"2002","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105573_bib32","first-page":"83","article-title":"Angiotensin-II receptor antagonist losartan dose-dependently improves the left ventricular remodelling in patients with congestive heart failure","volume":"5","author":"Berezin","year":"2002","journal-title":"J. Clin. Basic Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0735-1097(00)01158-X","article-title":"Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial","volume":"37","author":"Cice","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105573_bib35","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9149(00)00796-7","article-title":"Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group","volume":"85","author":"Witchitz","year":"2000","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.CIR.101.4.378","article-title":"Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study","volume":"101","author":"White","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105573_bib37","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S0002-8703(99)70083-9","article-title":"Metoprolol CR\/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction","volume":"138","author":"Goldstein","year":"1999","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2021.105573_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1071-9164(97)90013-0","article-title":"Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group","volume":"3","author":"Cohn","year":"1997","journal-title":"J. Card. Fail."},{"issue":"11","key":"10.1016\/j.phrs.2021.105573_bib39","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","article-title":"Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise","volume":"94","author":"Packer","year":"1996","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.phrs.2021.105573_bib40","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.94.11.2800","article-title":"Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group","volume":"94","author":"Colucci","year":"1996","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2021.105573_bib41","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/01.CIR.92.6.1499","article-title":"Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure","volume":"92","author":"Krum","year":"1995","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.CIR.92.2.212","article-title":"Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group","volume":"92","author":"Group","year":"1995","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0735-1097(95)80020-H","article-title":"Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure","volume":"26","author":"Dickstein","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0735-1097(97)00253-2","article-title":"Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators","volume":"30","author":"Lang","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105573_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4070\/kcj.2011.41.2.61","article-title":"Effect of valsartan on N-terminal pro-brain natriuretic peptide in patient with stable chronic heart failure: comparison with enalapril","volume":"41","author":"Lee","year":"2011","journal-title":"Korean Circ. J."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1388-9842(00)00078-7","article-title":"MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing","volume":"2","author":"Genth-Zotz","year":"2000","journal-title":"Eur. J. Heart Fail."},{"issue":"7","key":"10.1016\/j.phrs.2021.105573_bib47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/j.1552-4604.1995.tb04107.x","article-title":"Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group","volume":"35","author":"Beller","year":"1995","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/hrt.79.1.86","article-title":"Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol","volume":"79","author":"Sanderson","year":"1998","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1536\/ihj.19-231","article-title":"The impact of sacrubitril\/valsartan on clinical treatment and hs-cTnT and NT-ProBNP serum levels and the left ventricular function in patients with chronic heart failure","volume":"61","author":"Gao","year":"2019","journal-title":"Int. Heart J."},{"issue":"12","key":"10.1016\/j.phrs.2021.105573_bib50","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1093\/oxfordjournals.eurheartj.a060844","article-title":"Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy\/Safety Trial (FEST) Study Group","volume":"16","author":"Erhardt","year":"1995","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2021.105573_bib51","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J. Card. Fail."},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1536\/jhj.44.681","article-title":"Effects of spironolactone and metoprolol on QT dispersion in heart failure","volume":"44","author":"Akbulut","year":"2003","journal-title":"Jpn. Heart J."},{"issue":"7","key":"10.1016\/j.phrs.2021.105573_bib53","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","article-title":"Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure","volume":"50","author":"Chan","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105573_bib54","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1067\/mhj.2000.105302","article-title":"Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy","volume":"139","author":"Konstam","year":"2000","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib55","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0735-1097(02)02855-3","article-title":"Effect of spironolactone on cardiacsympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy","volume":"41","author":"Kasama","year":"2003","journal-title":"J. Am. College Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib56","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jjcc.2010.11.006","article-title":"Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure","volume":"57","author":"Kimura","year":"2011","journal-title":"J. Cardiol."},{"issue":"10","key":"10.1016\/j.phrs.2021.105573_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002962","article-title":"Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction","volume":"9","author":"Breathett","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10.1016\/j.phrs.2021.105573_bib58","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","article-title":"Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.phrs.2021.105573_bib59","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.CIR.91.10.2573","article-title":"Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy","volume":"91","author":"Greenberg","year":"1995","journal-title":"Circulation"},{"issue":"8885","key":"10.1016\/j.phrs.2021.105573_bib60","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0140-6736(93)92930-R","article-title":"Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group","volume":"342","author":"Waagstein","year":"1993","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.phrs.2021.105573_bib61","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/hrt.2003.015552","article-title":"Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study","volume":"90","author":"Bellenger","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.phrs.2021.105573_bib62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10557-008-6116-9","article-title":"Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial","volume":"22","author":"Dobre","year":"2008","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"8","key":"10.1016\/j.phrs.2021.105573_bib63","doi-asserted-by":"crossref","first-page":"12d","DOI":"10.1016\/0002-9149(89)90411-6","article-title":"Comparison of lisinopril versus placebo for congestive heart failure","volume":"63","author":"Lewis","year":"1989","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2021.105573_bib64","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/01.CIR.99.8.990","article-title":"Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure","volume":"99","author":"Hamroff","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105573_bib65","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0167-5273(02)00154-7","article-title":"Safety and efficacy of valsartan versus enalapril in heart failure patients","volume":"85","author":"Willenheimer","year":"2002","journal-title":"Int. J. Card."},{"issue":"11","key":"10.1016\/j.phrs.2021.105573_bib66","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New Engl. J.\u00a0Med."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib67","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0735-1097(01)01383-3","article-title":"Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction","volume":"38","author":"Stanek","year":"2001","journal-title":"J. Am. College Cardiol."},{"issue":"9","key":"10.1016\/j.phrs.2021.105573_bib68","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy","volume":"40","author":"Rousseau","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib69","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cardfail.2006.10.013","article-title":"Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure","volume":"13","author":"White","year":"2007","journal-title":"J. Card. Fail."},{"issue":"3","key":"10.1016\/j.phrs.2021.105573_bib70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1043-6618(02)00092-0","article-title":"Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease","volume":"46","author":"Martin","year":"2002","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib71","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/oxfordjournals.eurheartj.a015297","article-title":"Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials","volume":"18","author":"Doughty","year":"1997","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.phrs.2021.105573_bib72","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-134-7-200104030-00008","article-title":"Beta-blockers in congestive heart failure. A Bayesian meta-analysis","volume":"134","author":"Brophy","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib73","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 Years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib75","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"25","key":"10.1016\/j.phrs.2021.105573_bib76","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1161\/CIRCULATIONAHA.104.508093","article-title":"Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction","volume":"111","author":"Solomon","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib77","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1161\/01.CIR.94.5.1010","article-title":"Assessment of myocardial viability with 99mTc sestamibi in patients undergoing cardiac transplantation. A scintigraphic\/pathological study","volume":"94","author":"Medrano","year":"1996","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib78","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/CIRCHEARTFAILURE.111.961573","article-title":"Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction","volume":"4","author":"Wessler","year":"2011","journal-title":"Circ. Heart Fail."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib79","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jchf.2013.11.007","article-title":"Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis","volume":"2","author":"Savarese","year":"2014","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.phrs.2021.105573_bib80","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure","volume":"68","author":"Zile","year":"2016","journal-title":"J. Am. College Cardiol."},{"issue":"22","key":"10.1016\/j.phrs.2021.105573_bib81","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jacc.2016.10.001","article-title":"NT-proBNP: the gold standard biomarker in heart failure","volume":"68","author":"McKie","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib82","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.phrs.2021.105573_bib83","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in n-terminal pro-b-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.phrs.2021.105573_bib84","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jchf.2018.10.014","article-title":"NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF","volume":"7","author":"Daubert","year":"2019","journal-title":"JACC Heart Fail."},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib85","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/bcp.12012","article-title":"Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis","volume":"75","author":"Hu","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"31","key":"10.1016\/j.phrs.2021.105573_bib86","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib87","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jchf.2014.04.012","article-title":"\u201cTriple therapy\u201d of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn\u2019t we tell patients?","volume":"2","author":"Cole","year":"2014","journal-title":"JACC Heart Fail."},{"issue":"25","key":"10.1016\/j.phrs.2021.105573_bib88","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/eurheartj\/ehaa184","article-title":"A putative placebo analysis of the effects of sacubitril\/valsartan in heart failure across the full range of ejection fraction","volume":"41","author":"Vaduganathan","year":"2020","journal-title":"Eur. Heart J."},{"issue":"13","key":"10.1016\/j.phrs.2021.105573_bib89","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"10","key":"10.1016\/j.phrs.2021.105573_bib90","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2459\/JCM.0000000000000825","article-title":"Sacubitril\/valsartan improves medium-term reverse left ventricular remodeling: why wait?","volume":"20","author":"Santangelo","year":"2019","journal-title":"J. Cardiovasc. Med."},{"issue":"21","key":"10.1016\/j.phrs.2021.105573_bib91","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2021.105573_bib92","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10557-019-06892-y","article-title":"Effect of tofogliflozin on systolic and diastolic cardiac function in type 2 diabetic patients","volume":"33","author":"Otagaki","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.phrs.2021.105573_bib93","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12933-020-0987-x","article-title":"Effects of antidiabetic drugs on left ventricular function\/dysfunction: a systematic review and network meta-analysis","volume":"19","author":"Zhang","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"9","key":"10.1016\/j.phrs.2021.105573_bib94","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jacep.2019.07.012","article-title":"Left ventricular reverse remodeling in cardiac resynchronization therapy and long-term outcomes","volume":"5","author":"Naqvi","year":"2019","journal-title":"JACC Clin. Electrophysiol."},{"key":"10.1016\/j.phrs.2021.105573_bib95","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.hrthm.2006.06.031","article-title":"Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration","volume":"3","author":"Neelagaru","year":"2006","journal-title":"Heart Rhythm."},{"issue":"5","key":"10.1016\/j.phrs.2021.105573_bib96","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ehf2.12902","article-title":"A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life","volume":"7","author":"Giallauria","year":"2020","journal-title":"ESC Heart Fail."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:33:15Z","timestamp":1760913195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":96,"alternative-id":["S1043661821001572"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105573","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105573"}}